ArticleFrontiers in oncology2025
Corded and hyalinized endometrioid carcinoma: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corded and hyalinized endometrioid carcinoma (CHEC) is a rare morphological subtype of endometrioid carcinoma (EC), characterized by a biphasic pattern consisting of epithelial or spindled tumor cells embedded within hyalinized stroma, merging with conventional low-grade EC. We present a case of CHEC in a 24-year-old woman who presented with irregular vaginal bleeding. Imaging showed a mass protruding toward the cervix, and subsequent tumor resection confirmed the diagnosis of CHEC. Immunohistochemical staining for β-catenin and CTNNB1 gene mutation analysis were helpful in the diagnosis of CHEC, and molecular subtyping provided valuable prognostic information to a certain extent. Postoperatively, the patient received progestin therapy for 6 months and remained recurrence-free. Given the rarity of CHEC, distinguishing this disease from other biphasic uterine tumors is crucial. This report aims to enhance recognition of this rare entity, facilitating its accurate diagnosis and preventing inappropriate therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.